Psychometric Properties of the GAD-7 (General Anxiety Disorder-7): a Cross-sectional Study of the Peruvian General Population

Overview

Journal BMC Psychol

Publisher Biomed Central

Specialty Psychology

Date 2024 Apr 2

PMID 38566138

Authors

David Villarreal-Zegarra

Rubi Paredes-Angeles

Nikol Mayo-Puchoc

Enoc Arenas-Minaya

Jeff Huarcaya-Victoria

Anthony Copez-Lonzoy

Affiliations

Soon will be listed here.

Abstract

Background: Anxiety disorders are among the main mental health problems worldwide and are considered one of the most disabling conditions. Therefore, it is essential to have measurement tools that can be used to screen for anxiety symptoms in the general population and thus identify potential cases of people with anxiety symptoms and provide them with timely care. Our aim was to evaluate the psychometric properties of the General Anxiety Disorder-7 scale (GAD-7) in the Peruvian population.

Method: Our study was a cross-sectional study. The sample included people aged 12 to 65 years in Peru. Confirmatory factor analysis, analysis of measurement invariance, convergent validity with the Patient Health Questionnaire-9 (PHQ-9) and internal consistency analysis were performed.

Results: In total, 4431 participants were included. The one-factor model showed the best fit (CFI = 0.994; TLI = 0.991; RMSEA = 0.068; WRMR = 1.567). The GAD-7 score showed measurement invariance between men and women and between age groups (adults vs. adolescents) (ΔCFI < 0.01). The internal consistency of the one-factor model was satisfactory (ω = 0.90, α = 0.93). The relationship between depressive symptoms (PHQ-9) and anxiety symptoms (GAD-7) presented a moderate correlation (r = 0.77).

Conclusions: Our study concluded that the GAD-7 score shows evidence of validity and reliability for the one-factor model. Furthermore, because the GAD-7 score is invariant, comparisons can be made between groups (i.e., by sex and age group). Finally, we recommend the use of the GAD-7 for the general population in the Peruvian context.

Citing Articles

Internal Validity and Reliability of the GAD-7 Test in Latin America.

Lopez N, Morales-Asencio B, Ripoll-Cordoba D, Coronado-Lopez J, Caldichoury N, Quispe-Ayala C Chronic Stress (Thousand Oaks). 2025; 9:24705470251315260.

PMID: 40079046 PMC: 11898021. DOI: 10.1177/24705470251315260.

Responding to old problems in the Dutch work addiction scale: a psychometric approach in a Peruvian sample.

Salas-Blas E, Vallejos-Flores M, Calderon-De la Cruz G, Manzanares-Medina E, Fonseca-Pedrero E, Mayo-Puchoc N BMC Psychol. 2025; 13(1):155.

PMID: 39987134 PMC: 11847342. DOI: 10.1186/s40359-025-02437-1.

Factorial invariance of the generalized anxiety disorder scale (GAD-7) in Latin America and the Caribbean.

Lopez N, Coronado J, Ripoll-Cordoba D, Caldichoury N, Quispe-Ayala C, Morales-Asencio B Front Psychiatry. 2025; 16:1529424.

PMID: 39950169 PMC: 11821638. DOI: 10.3389/fpsyt.2025.1529424.

Postacute Myocardial Infarction Differences in Physical Activity Behavior, Anxiety, and Depression Levels.

Shajrawi A, Al-Akash H, Al-Smadi A, Masadeh R, AbuRuz M, Khalil H SAGE Open Nurs. 2024; 10:23779608241304478.

PMID: 39734763 PMC: 11672469. DOI: 10.1177/23779608241304478.

References

Teymoori A, Real R, Gorbunova A, Haghish E, Andelic N, Wilson L . Measurement invariance of assessments of depression (PHQ-9) and anxiety (GAD-7) across sex, strata and linguistic backgrounds in a European-wide sample of patients after Traumatic Brain Injury. J Affect Disord. 2019; 262:278-285. DOI: 10.1016/j.jad.2019.10.035. View

Stochl J, Fried E, Fritz J, Croudace T, Russo D, Knight C . On Dimensionality, Measurement Invariance, and Suitability of Sum Scores for the PHQ-9 and the GAD-7. Assessment. 2020; 29(3):355-366. DOI: 10.1177/1073191120976863. View

Gonzales-Castillo J, Varona-Castillo L, Dominguez-Morante M, Ocana-Gutierrez V . [COVID-19 pandemic and Public Health Policies in Peru: March-May 2020]. Rev Salud Publica (Bogota). 2023; 22(2):155-163. DOI: 10.15446/rsap.V22n2.87373. View

Beck A, Epstein N, Brown G, Steer R . An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988; 56(6):893-7. DOI: 10.1037//0022-006x.56.6.893. View

Villarreal-Zegarra D, Barrera-Begazo J, Otazu-Alfaro S, Mayo-Puchoc N, Bazo-Alvarez J, Huarcaya-Victoria J . Sensitivity and specificity of the Patient Health Questionnaire (PHQ-9, PHQ-8, PHQ-2) and General Anxiety Disorder scale (GAD-7, GAD-2) for depression and anxiety diagnosis: a cross-sectional study in a Peruvian hospital population. BMJ Open. 2023; 13(9):e076193. PMC: 10510859. DOI: 10.1136/bmjopen-2023-076193. View

. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021; 398(10312):1700-1712. PMC: 8500697. DOI: 10.1016/S0140-6736(21)02143-7. View

Galindo-Vazquez O, Ramirez-Orozco M, Costas-Muniz R, Mendoza-Contreras L, Calderillo-Ruiz G, Meneses-Garcia A . Symptoms of anxiety, depression and self-care behaviors during the COVID-19 pandemic in the general population. Gac Med Mex. 2020; 156(4):298-305. PMC: 8327400. DOI: 10.24875/GMM.20000266. View

Flora D, Curran P . An empirical evaluation of alternative methods of estimation for confirmatory factor analysis with ordinal data. Psychol Methods. 2004; 9(4):466-91. PMC: 3153362. DOI: 10.1037/1082-989X.9.4.466. View

Balsamo M, Cataldi F, Carlucci L, Fairfield B . Assessment of anxiety in older adults: a review of self-report measures. Clin Interv Aging. 2018; 13:573-593. PMC: 5896683. DOI: 10.2147/CIA.S114100. View

10.

Kroenke K, Spitzer R, Williams J . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9):606-13. PMC: 1495268. DOI: 10.1046/j.1525-1497.2001.016009606.x. View

11.

Liang Y, Wu K, Zhou Y, Huang X, Zhou Y, Liu Z . Mental Health in Frontline Medical Workers during the 2019 Novel Coronavirus Disease Epidemic in China: A Comparison with the General Population. Int J Environ Res Public Health. 2020; 17(18). PMC: 7558595. DOI: 10.3390/ijerph17186550. View

12.

Levis B, Benedetti A, Thombs B . Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019; 365:l1476. PMC: 6454318. DOI: 10.1136/bmj.l1476. View

13.

Spitzer R, Kroenke K, Williams J, Lowe B . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166(10):1092-7. DOI: 10.1001/archinte.166.10.1092. View

14.

Kola L, Kohrt B, Hanlon C, Naslund J, Sikander S, Balaji M . COVID-19 mental health impact and responses in low-income and middle-income countries: reimagining global mental health. Lancet Psychiatry. 2021; 8(6):535-550. PMC: 9764935. DOI: 10.1016/S2215-0366(21)00025-0. View

15.

Stocker R, Tran T, Hammarberg K, Nguyen H, Rowe H, Fisher J . Patient Health Questionnaire 9 (PHQ-9) and General Anxiety Disorder 7 (GAD-7) data contributed by 13,829 respondents to a national survey about COVID-19 restrictions in Australia. Psychiatry Res. 2021; 298:113792. PMC: 9754708. DOI: 10.1016/j.psychres.2021.113792. View

16.

Plummer F, Manea L, Trepel D, McMillan D . Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016; 39:24-31. DOI: 10.1016/j.genhosppsych.2015.11.005. View

17.

Akoglu H . User's guide to correlation coefficients. Turk J Emerg Med. 2018; 18(3):91-93. PMC: 6107969. DOI: 10.1016/j.tjem.2018.08.001. View

18.

Shrestha S, Ramos K, Fletcher T, Kraus-Schuman C, Stanley M, Ramsey D . Psychometric properties of worry and anxiety measures in a sample of african american and caucasian older adults. Aging Ment Health. 2019; 24(2):315-321. DOI: 10.1080/13607863.2018.1544217. View

19.

Lovibond P, LOVIBOND S . The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995; 33(3):335-43. DOI: 10.1016/0005-7967(94)00075-u. View

20.

Shih Y, Chou C, Lu Y, Yu H . Reliability and validity of the traditional Chinese version of the GAD-7 in Taiwanese patients with epilepsy. J Formos Med Assoc. 2022; 121(11):2324-2330. DOI: 10.1016/j.jfma.2022.04.018. View